Tag: release

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

TEL AVIV, Israel, June 14, 2026 (GLOBE NEWSWIRE) -- Orbs, the decentralized Layer-3 blockchain infrastructure focused on advanced on-chain trading, today announced Orbs Institutional, a new offering that provides trading desks, OTC firms, treasuries, custodians and financial platforms with direct access to its on-chain execution infrastructure.

TORONTO, June 14, 2026 (GLOBE NEWSWIRE) -- Stake has announced the availability of its referral code SHIMA, providing eligible new users with access to a promotional package that includes a 200% welcome bonus and up to 5% cashback rewards. The offer is designed to enhance the onboarding experience for new account holders and provide additional value through ongoing promotional benefits.

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 3, 2026.

Announced at FIRSTCON26, Modat brings Passive DNS to Magnify: one pivot from any signal to every related piece of attacker infrastructure

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab’s potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU.

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –